Clinical Trials Logo

Filter by:
NCT ID: NCT05045053 Recruiting - Corneal Disease Clinical Trials

Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

NCT ID: NCT05043311 Recruiting - COVID-19 Clinical Trials

The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.

Start date: December 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.

NCT ID: NCT05043285 Recruiting - COVID-19 Clinical Trials

The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.

Start date: December 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.

NCT ID: NCT05033847 Active, not recruiting - COVID-19 Pneumonia Clinical Trials

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Start date: September 12, 2021
Phase: Phase 2
Study type: Interventional

This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive one dose of recombinant COVID-19 vaccine sequentially at different shedules of 1-3 months, 3-6 months and ≥ 6 months after two doses of vaccination, and the subjects vaccinated at different schedules will be randomly assigned to different sequential immunization groups. At the same time, each sequential immunization group will be matched with a control group with the inactivated COVID-19 vaccine (vero cells) as the booster dose.

NCT ID: NCT05020873 Terminated - Sickle Cell Disease Clinical Trials

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

SPOTLIGHT
Start date: November 4, 2021
Phase:
Study type: Observational

This is a multicenter, prospective, single-arm observational non-interventional study (NIS), which will be conducted in various countries in the Middle East and India.

NCT ID: NCT05016362 Recruiting - Eyelid Diseases Clinical Trials

Medial Fat Pad Preservation in Upper Eyelid Blepharoplasty

Start date: December 24, 2020
Phase:
Study type: Observational

Medial upper eyelid pad of fat bulge is a common problem. medial fat pad preservation might be a good adjutant to upper eyelid blepharoplasty

NCT ID: NCT05001269 Recruiting - Clinical trials for Primary Hyperoxaluria

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

PHYOX8
Start date: February 22, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.

NCT ID: NCT04991051 Completed - Clinical trials for Fallopian Tube Cancer

Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer

HALO
Start date: May 2, 2021
Phase:
Study type: Observational

To maximise the accessibility and benefit of PARP inhibitors to eligible patients, it is essential to know the prevalence of HRD in women with advanced high-grade serous or endometrioid ovarian cancer. Presently, the prevalence data for HRD are available from selected geographies only and range from 31% to 50%. Furthermore, the risk factors associated with HRD and clinical characteristics of patients with HRD need exploration for region-specific differences. In the present study, we will estimate the region- and country-specific prevalence of HRD in women with stage III or IV high-grade serous or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer and associated risk factors with clinical characteristics in Asia-Pacific countries, Latin America, Africa, Russia, Australia, and Middle East countries. The findings of the study will help the oncologists in optimal patient selection and clinical decision-making for the first-line maintenance of patients with HGSOC

NCT ID: NCT04971590 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis

Start date: September 14, 2021
Phase:
Study type: Observational

This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates [UAE], Qatar, Bahrain, Kuwait and Oman).

NCT ID: NCT04969575 Recruiting - Infertility Clinical Trials

A Benchtop Incubator Prospective Study

Start date: July 15, 2021
Phase:
Study type: Observational

The use of extended embryo culture to the blastocyst stage and preimplantation genetic testing for aneuploidy (PGT-A) has enabled identification and selection of embryos with the best developmental potential and improved in vitro fertilization (IVF) clinical outcomes. While numerous types of commercially available human embryo culture media exist for culture to the blastocyst stage, the impact of culture conditions on blastocyst development and aneuploidy formation is not well understood. Culture conditions are very important for the success of the IVF cycle, many of the factors involved in the process have been extensively studied, including the use of sequential culture medium vs single step culture medium, humidified incubators vs dry incubators and refreshing the medium on day 3 vs uninterrupted culture till day 5. However, none of the studies investigated the effect on euploid rate in a sibling oocyte design with PGT-A, which requires culture till day 7.